872141-25-8

Basic information

• Product Name: 2-(3-Fluoro-2-nitrophenyl)acetic acid
• Synonyms: 2-(3-Fluoro-2-nitrophenyl)acetic acid;3-Fluoro-2-nitrobenzeneacetic acid;2-(3-Fluoro-2-nitrophenyl)
• CAS NO: 872141-25-8
• Molecular Formula: C₈H₆FNO₄
• Molecular Weight: 199.1359432
• Mol File: 872141-25-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-(3-Fluoro-2-nitrophenyl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-Fluoro-2-nitrophenyl)acetic acid(872141-25-8)
• EPA Substance Registry System: 2-(3-Fluoro-2-nitrophenyl)acetic acid(872141-25-8)

Safety Data

• Hazardous Substances Data: 872141-25-8(Hazardous Substances Data)

Usage

Uses

(3-Fluoro-2-nitrophenyl)acetic acid

Upstream product

• 19064-24-5 2,6-difluoro-1-nitrobenzene 
• 872141-24-7 2-(3-fluoro-2-nitrophenyl)malonic acid dimethyl ester 

Downstream Products

• 71294-03-6 7-fluoro-1,3-dihydro-indol-2-one 
• 956407-06-0 N-(1-benzyl-piperidin-4-yl)-2-(3-fluoro-2-nitrophenyl)-acetamide 
• 956407-07-1 (1-benzyl-piperidin-4-yl)-[2-(3-fluoro-2-nitro-phenyl)-ethyl]-amine 
• 956407-10-6 3-(1-benzyl-piperidin-4-yl)-9-fluoro-1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one 
• 956407-09-3 [2-(2-amino-3-fluorophenyl)-ethyl]-(1-benzyl-piperidin-4-yl)-amine 

Relevant articles and documents

CGRP ANTAGONISTS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.